Yue Peng, Ping Zhao, Juan Tan, Rui Liu, Yiping Zheng
{"title":"Effect of Tafluprost on 24-Hour Intraocular Pressure in Patients with Primary Open Angle Glaucoma and Ocular Hypertension","authors":"Yue Peng, Ping Zhao, Juan Tan, Rui Liu, Yiping Zheng","doi":"10.3760/CMA.J.ISSN.1674-845X.2020.01.005","DOIUrl":null,"url":null,"abstract":"Objective: \nTo evaluate the 24-hour efficacy of tafluprost on the reduction of intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). \n \n \nMethods: \nIn this case-series study, a total of 43 eyes of 22 newly diagnosed patients with POAG and OHT from Shengyang Aier Eye Hospital were enrolled. All patients were trained to use an Icare HOME tonometer to measure IOP by themselves. For the certificated patients, aphysician used GAT to measure their IOP three times, and then the patients used Icare HOME to measure 24-hour IOP by themselves. Patients was given tafluprost once a day at 21∶00. Icare HOME was used by the patients themselves to measure 24-hour IOP again one month later. A one-way ANOVA and Bland-Altman analysis were used to compare the consistency of the GAT used by a physician and the Icare HOME used by patients to measure IOP. A paired t test was used to compare IOP at each time point, the mean, the peak, the valley and the fluctuation of 24-hour IOP before and after treatment with tafluprost. \n \n \nResults: \nThe mean IOPs measured with GAT by a physician and Icare HOME by patients were 18.2±3.7 mmHg (1 mmHg=0.133 kPa) and 17.4±4.2 mmHg, respectively, with no statistically significant difference (F=0.837, P=0.363). Bland-Altman analysis showed that there was a good consistency between GAT measured by a physician and Icare HOME measured by patients. IOP decreased at all time points of assessment after 1 month (all P<0.05). The range of IOP reduction at different time points was 1.8 to 5.5 mmHg (all P<0.05). The mean, the peak, the valley, and the fluctuation of IOP at baseline were 19.4±5.0, 25.0±5.8, 14.1±4.5 and 10.9±3.8 mmHg, respectively, and were reduced to 15.6±4.2, 20.4±4.5, 11.3±3.6 and 9.2±2.9 mmHg after treatment (t=9.450, 9.636, 5.939, 3.137, all P<0.05). \n \n \nConclusions: \nTafluprost provides effective 24-hour IOP reduction in newly diagnosed patients with POAG and OHT. \n \n \nKey words: \nglaucoma, open-angle; ocular hypertension; tonometry, ocular; tafluprost","PeriodicalId":10142,"journal":{"name":"Chinese Journal of Optometry & Ophthalmology","volume":"10 1","pages":"27-31"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Optometry & Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-845X.2020.01.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective:
To evaluate the 24-hour efficacy of tafluprost on the reduction of intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT).
Methods:
In this case-series study, a total of 43 eyes of 22 newly diagnosed patients with POAG and OHT from Shengyang Aier Eye Hospital were enrolled. All patients were trained to use an Icare HOME tonometer to measure IOP by themselves. For the certificated patients, aphysician used GAT to measure their IOP three times, and then the patients used Icare HOME to measure 24-hour IOP by themselves. Patients was given tafluprost once a day at 21∶00. Icare HOME was used by the patients themselves to measure 24-hour IOP again one month later. A one-way ANOVA and Bland-Altman analysis were used to compare the consistency of the GAT used by a physician and the Icare HOME used by patients to measure IOP. A paired t test was used to compare IOP at each time point, the mean, the peak, the valley and the fluctuation of 24-hour IOP before and after treatment with tafluprost.
Results:
The mean IOPs measured with GAT by a physician and Icare HOME by patients were 18.2±3.7 mmHg (1 mmHg=0.133 kPa) and 17.4±4.2 mmHg, respectively, with no statistically significant difference (F=0.837, P=0.363). Bland-Altman analysis showed that there was a good consistency between GAT measured by a physician and Icare HOME measured by patients. IOP decreased at all time points of assessment after 1 month (all P<0.05). The range of IOP reduction at different time points was 1.8 to 5.5 mmHg (all P<0.05). The mean, the peak, the valley, and the fluctuation of IOP at baseline were 19.4±5.0, 25.0±5.8, 14.1±4.5 and 10.9±3.8 mmHg, respectively, and were reduced to 15.6±4.2, 20.4±4.5, 11.3±3.6 and 9.2±2.9 mmHg after treatment (t=9.450, 9.636, 5.939, 3.137, all P<0.05).
Conclusions:
Tafluprost provides effective 24-hour IOP reduction in newly diagnosed patients with POAG and OHT.
Key words:
glaucoma, open-angle; ocular hypertension; tonometry, ocular; tafluprost